Therapeutic potential of atrial natriuretic peptide administration on peripheral arterial diseases

Kwijun Park, Hiroshi Itoh, Kenichi Yamahara, Masakatsu Sone, Kazutoshi Miyashita, Naofumi Oyamada, Naoya Sawada, Daisuke Taura, Megumi Inuzuka, Takuhiro Sonoyama, Hirokazu Tsujimoto, Yasutomo Fukunaga, Naohisa Tamura, Kazuwa Nakao

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Peripheral arterial diseases are caused by arterial sclerosis and impaired collateral vessel formation, which are exacerbated by diabetes, often leading to leg amputation. We have reported that an activation of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway accelerated vascular regeneration and blood flow recovery in murine legs, for which ischemia had been induced by a femoral arterial ligation as a model for peripheral arterial diseases. In this study, ip injection of carperitide, a human recombinant atrial natriuretic peptide, accelerated blood flow recovery with increasing capillary density in ischemic legs not only in nondiabetic mice but also in mice kept upon streptozotocin-induced hyperglycemia for 16 wk, which significantly impaired the blood flow recovery compared with nondiabetic mice. Based on these findings, we tried to apply the administration of carperitide to the treatment of peripheral arterial diseases. The study group comprised a continuous series of 13 patients with peripheral arterial diseases (Fontaine's classification I, one; II, five; III, two; and IV, five), for whom conventional therapies had not accomplished appreciable results. Carperitide was administrated continuously and intravenously for 2 wk to Fontaine's class I-III patients and for 4 weeks to class IV patients. The dose was gradually increased to the maximum, with the patient's systolic blood pressure being kept above 100 mm Hg. Carperitide administration improved the ankle-brachial pressure index, intermittent claudication, rest pain, and ulcers. In conclusion, this study showed a therapeutic potential of carperitide to treat peripheral arterial diseases refractory to conventional therapies.

Original languageEnglish
Pages (from-to)483-491
Number of pages9
JournalEndocrinology
Volume149
Issue number2
DOIs
Publication statusPublished - 2008 Feb

Fingerprint

Peripheral Arterial Disease
Atrial Natriuretic Factor
Leg
Blood Pressure
Therapeutics
Cyclic GMP-Dependent Protein Kinases
Ankle Brachial Index
Intermittent Claudication
Natriuretic Peptides
Sclerosis
Streptozocin
Thigh
Amputation
Hyperglycemia
Ulcer
Ligation
Blood Vessels
Regeneration
Ischemia
human NPPA protein

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Park, K., Itoh, H., Yamahara, K., Sone, M., Miyashita, K., Oyamada, N., ... Nakao, K. (2008). Therapeutic potential of atrial natriuretic peptide administration on peripheral arterial diseases. Endocrinology, 149(2), 483-491. https://doi.org/10.1210/en.2007-1094

Therapeutic potential of atrial natriuretic peptide administration on peripheral arterial diseases. / Park, Kwijun; Itoh, Hiroshi; Yamahara, Kenichi; Sone, Masakatsu; Miyashita, Kazutoshi; Oyamada, Naofumi; Sawada, Naoya; Taura, Daisuke; Inuzuka, Megumi; Sonoyama, Takuhiro; Tsujimoto, Hirokazu; Fukunaga, Yasutomo; Tamura, Naohisa; Nakao, Kazuwa.

In: Endocrinology, Vol. 149, No. 2, 02.2008, p. 483-491.

Research output: Contribution to journalArticle

Park, K, Itoh, H, Yamahara, K, Sone, M, Miyashita, K, Oyamada, N, Sawada, N, Taura, D, Inuzuka, M, Sonoyama, T, Tsujimoto, H, Fukunaga, Y, Tamura, N & Nakao, K 2008, 'Therapeutic potential of atrial natriuretic peptide administration on peripheral arterial diseases', Endocrinology, vol. 149, no. 2, pp. 483-491. https://doi.org/10.1210/en.2007-1094
Park, Kwijun ; Itoh, Hiroshi ; Yamahara, Kenichi ; Sone, Masakatsu ; Miyashita, Kazutoshi ; Oyamada, Naofumi ; Sawada, Naoya ; Taura, Daisuke ; Inuzuka, Megumi ; Sonoyama, Takuhiro ; Tsujimoto, Hirokazu ; Fukunaga, Yasutomo ; Tamura, Naohisa ; Nakao, Kazuwa. / Therapeutic potential of atrial natriuretic peptide administration on peripheral arterial diseases. In: Endocrinology. 2008 ; Vol. 149, No. 2. pp. 483-491.
@article{18dba74716244f26a47813e535ed1d1f,
title = "Therapeutic potential of atrial natriuretic peptide administration on peripheral arterial diseases",
abstract = "Peripheral arterial diseases are caused by arterial sclerosis and impaired collateral vessel formation, which are exacerbated by diabetes, often leading to leg amputation. We have reported that an activation of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway accelerated vascular regeneration and blood flow recovery in murine legs, for which ischemia had been induced by a femoral arterial ligation as a model for peripheral arterial diseases. In this study, ip injection of carperitide, a human recombinant atrial natriuretic peptide, accelerated blood flow recovery with increasing capillary density in ischemic legs not only in nondiabetic mice but also in mice kept upon streptozotocin-induced hyperglycemia for 16 wk, which significantly impaired the blood flow recovery compared with nondiabetic mice. Based on these findings, we tried to apply the administration of carperitide to the treatment of peripheral arterial diseases. The study group comprised a continuous series of 13 patients with peripheral arterial diseases (Fontaine's classification I, one; II, five; III, two; and IV, five), for whom conventional therapies had not accomplished appreciable results. Carperitide was administrated continuously and intravenously for 2 wk to Fontaine's class I-III patients and for 4 weeks to class IV patients. The dose was gradually increased to the maximum, with the patient's systolic blood pressure being kept above 100 mm Hg. Carperitide administration improved the ankle-brachial pressure index, intermittent claudication, rest pain, and ulcers. In conclusion, this study showed a therapeutic potential of carperitide to treat peripheral arterial diseases refractory to conventional therapies.",
author = "Kwijun Park and Hiroshi Itoh and Kenichi Yamahara and Masakatsu Sone and Kazutoshi Miyashita and Naofumi Oyamada and Naoya Sawada and Daisuke Taura and Megumi Inuzuka and Takuhiro Sonoyama and Hirokazu Tsujimoto and Yasutomo Fukunaga and Naohisa Tamura and Kazuwa Nakao",
year = "2008",
month = "2",
doi = "10.1210/en.2007-1094",
language = "English",
volume = "149",
pages = "483--491",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Therapeutic potential of atrial natriuretic peptide administration on peripheral arterial diseases

AU - Park, Kwijun

AU - Itoh, Hiroshi

AU - Yamahara, Kenichi

AU - Sone, Masakatsu

AU - Miyashita, Kazutoshi

AU - Oyamada, Naofumi

AU - Sawada, Naoya

AU - Taura, Daisuke

AU - Inuzuka, Megumi

AU - Sonoyama, Takuhiro

AU - Tsujimoto, Hirokazu

AU - Fukunaga, Yasutomo

AU - Tamura, Naohisa

AU - Nakao, Kazuwa

PY - 2008/2

Y1 - 2008/2

N2 - Peripheral arterial diseases are caused by arterial sclerosis and impaired collateral vessel formation, which are exacerbated by diabetes, often leading to leg amputation. We have reported that an activation of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway accelerated vascular regeneration and blood flow recovery in murine legs, for which ischemia had been induced by a femoral arterial ligation as a model for peripheral arterial diseases. In this study, ip injection of carperitide, a human recombinant atrial natriuretic peptide, accelerated blood flow recovery with increasing capillary density in ischemic legs not only in nondiabetic mice but also in mice kept upon streptozotocin-induced hyperglycemia for 16 wk, which significantly impaired the blood flow recovery compared with nondiabetic mice. Based on these findings, we tried to apply the administration of carperitide to the treatment of peripheral arterial diseases. The study group comprised a continuous series of 13 patients with peripheral arterial diseases (Fontaine's classification I, one; II, five; III, two; and IV, five), for whom conventional therapies had not accomplished appreciable results. Carperitide was administrated continuously and intravenously for 2 wk to Fontaine's class I-III patients and for 4 weeks to class IV patients. The dose was gradually increased to the maximum, with the patient's systolic blood pressure being kept above 100 mm Hg. Carperitide administration improved the ankle-brachial pressure index, intermittent claudication, rest pain, and ulcers. In conclusion, this study showed a therapeutic potential of carperitide to treat peripheral arterial diseases refractory to conventional therapies.

AB - Peripheral arterial diseases are caused by arterial sclerosis and impaired collateral vessel formation, which are exacerbated by diabetes, often leading to leg amputation. We have reported that an activation of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway accelerated vascular regeneration and blood flow recovery in murine legs, for which ischemia had been induced by a femoral arterial ligation as a model for peripheral arterial diseases. In this study, ip injection of carperitide, a human recombinant atrial natriuretic peptide, accelerated blood flow recovery with increasing capillary density in ischemic legs not only in nondiabetic mice but also in mice kept upon streptozotocin-induced hyperglycemia for 16 wk, which significantly impaired the blood flow recovery compared with nondiabetic mice. Based on these findings, we tried to apply the administration of carperitide to the treatment of peripheral arterial diseases. The study group comprised a continuous series of 13 patients with peripheral arterial diseases (Fontaine's classification I, one; II, five; III, two; and IV, five), for whom conventional therapies had not accomplished appreciable results. Carperitide was administrated continuously and intravenously for 2 wk to Fontaine's class I-III patients and for 4 weeks to class IV patients. The dose was gradually increased to the maximum, with the patient's systolic blood pressure being kept above 100 mm Hg. Carperitide administration improved the ankle-brachial pressure index, intermittent claudication, rest pain, and ulcers. In conclusion, this study showed a therapeutic potential of carperitide to treat peripheral arterial diseases refractory to conventional therapies.

UR - http://www.scopus.com/inward/record.url?scp=38549171466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549171466&partnerID=8YFLogxK

U2 - 10.1210/en.2007-1094

DO - 10.1210/en.2007-1094

M3 - Article

C2 - 17991722

AN - SCOPUS:38549171466

VL - 149

SP - 483

EP - 491

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 2

ER -